KIRA-7|1937235-76-1|-陌孚医药/Medlife

您当前的位置：

KIRA-7

目录号: PL02691 纯度: ≥98%

CAS No. :1937235-76-1

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	KIRA-7
英文名称	KIRA-7
英文别名	KIRA7;KIRA-7;1-(4-(8-Amino-3-(1-methylcyclopropyl)imidazo[1,5-a]pyrazin-1-yl)naphthalen-1-yl)-3-(3-fluorophenyl)urea;KIRA analog, 13;BDBM192731
Cas No.	1937235-76-1
分子式	C₂₇H₂₃FN₆O
分子量	466.51
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情	KIRA-7 是一种咪唑并吡嗪化合物，可与 IRE1α 激酶结合 (IC₅₀ 为 110 nM) 以变构方式抑制其 RNase 活性。KIRA-7 具有抗纤维化作用。
生物活性	KIRA-7, an imidazopyrazine compound, binds the IRE1α kinase (IC 50 of 110 nM) to allosterically inhibit its RNase activity. KIRA-7 has an anti-fibrotic effect.
性状	Solid
IC50 & Target[1][2]	IC50: 110 nM (IRE1α kinase)
体外研究(In Vitro)	KIRA-7 can inhibit XBP1 splicing in the alveolar epithelial cell line MLE12. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)	KIRA-7 (5 mg/kg; intraperitoneal injection; daily for 14 days; C57BL6 mice) treatment results in decreased spliced XBP1 and ATF4, compared to bleomycin exposed mice treated with vehicle. Likewise, mRNA levels of BiP and CHOP are significantly elevated after Bleomycin exposure, and treatment of Bleomycin-exposed mice with KIRA-7 decreased these levels. mRNA levels of collagen 1A1 and fibronectin are both significantly decreased by KIRA-7 treatment. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Powder -20°C 3 years；4°C 2 years
参考文献	[1]. Thamsen M, et al. Small molecule inhibition of IRE1α kinase/RNase has anti-fibrotic effects in the lung. PLoS One. 2019 Jan 9;14(1):e0209824.

搜索质检报告(COA)

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品